Leukaemia

Signal: Faron’s blood cancer drug bexmarilimab continues to impress

Finnish biopharmaceutical Faron Pharmaceuticals has posted updated results of its phase I/II clinical trial for blood cancer drug bexmarilimab. The…

Syndax leukaemia drug hits endpoint goals ahead of planned new drug application

Clinical-stage biopharmaceutical company, Syndax, has announced that it has met one of its goals as part of a Phase I/II…